YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations. It demonstrates notable antitumor efficacy, inducing tumor regression in EGFRex20ins-driven patient-derived xenograft (PDX) models [1].
Molecular Weight:
500.6
CAS Number:
[2064269-82-3]
Formula:
C27H32N8O2
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
